LexaGene Holdings Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD from Q1 2021 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
LexaGene Holdings Inc. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents history and growth rate from Q1 2021 to Q4 2022.
  • LexaGene Holdings Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending November 30, 2022 was $464K, a 72.9% decline year-over-year.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2022 $464K -$1.25M -72.9% Nov 30, 2022 10-Q 2023-01-17
Q3 2022 $1.09M -$3.13M -74.2% Aug 31, 2022 10-Q 2022-10-18
Q1 2022 $4.72M -$4.9M -50.9% Feb 28, 2022 10-Q 2023-01-17
Q4 2021 $1.72M Nov 30, 2021 10-Q 2023-01-17
Q3 2021 $4.22M Aug 31, 2021 10-Q 2022-10-18
Q1 2021 $9.62M Feb 28, 2021 10-Q 2023-01-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.